Vol. 2 No. 11 (2022)
Reimbursement Reviews

Dostarlimab (Jemperli)

Published November 25, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses dostarlimab (Jemperli), solution for infusion, 500 mg/10 mL vial (50 mg/mL).
  • Indication: Monotherapy for the treatment of adults with dMMR or MSI-H recurrent or advanced endometrial cancer that has progressed on or after prior treatment with a platinum-containing regimen.